Skip to main content

Table 1 Baseline characteristics of participants by quartiles of serum trans fatty acids

From: Serum trans fatty acids, asymmetric dimethylarginine and risk of acute myocardial infarction and mortality in patients with suspected coronary heart disease: a prospective cohort study

  

Quartiles of serum trans fatty acids (wt%)

 

Total

Q1

Q2

Q3

Q4

 

0.30 (0.10, 0.36)a

0.41 (0.37, 0.45)

0.51 (0.46, 0.55)

0.64 (0.56, 1.61)

n = 1364

n = 355

n = 325

n = 331

n = 353

p-trendb

Demographic and clinical characteristics

      

Male sexc

1019 (74.7)

296 (83.4)

240 (73.8)

239 (72.2)

244 (69.1)

<0.001

Age (years)d

61 (54, 69)

57 (51, 63)

61 (54, 68)

64 (56, 71)

65 (55, 72)

<0.001

BMI (kg/m2)

26.2 (24.1, 28.7)

26.7 (24.4, 29.0)

26.0 (24.3, 28.7)

26.1 (24.0, 28.7)

26.1 (23.8, 28.7)

0.11

Fasting

187 (14.5)

69 (20.7)

46 (15.0)

34 (10.7)

38 (11.4)

<0.001

Diastolic blood pressure (mmHg)

80 (75, 88)

81 (75, 90)

80 (75, 87)

80 (74, 87)

80 (74, 89)

1.00

Systolic blood pressure (mmHg)

138 (125, 152)

139 (126, 154)

139 (125, 150)

136 (124, 150)

137 (122, 154)

0.08

Cardiovascular history

      

Previous AMI

553 (40.5)

140 (39.4)

126 (38.8)

137 (41.4)

150 (42.5)

0.84

Previous PCI

239 (17.5)

83 (23.4)

61 (18.8)

45 (13.6)

50 (14.2)

<0.01

Previous CABG

134 (9.8)

32 (9.0)

38 (11.7)

33 (10.0)

31 (8.8)

0.70

Risk factors

      

Impaired ejection fraction

151 (11.1)

42 (11.8)

30 (9.2)

38 (11.5)

41 (11.6)

0.98

Diabetes

140 (10.3)

38 (10.7)

26 (8.0)

33 (10.0)

43 (12.2)

0.71

Current smoker

457 (33.5)

158 (44.5)

101 (31.1)

92 (27.8)

106 (30.0)

0.05

Clinical diagnosis before baseline coronary angiography

    

Stable angina

1273 (93.3)

318 (89.6)

296 (91.1)

315 (95.2)

344 (97.5)

<0.001

Acute coronary syndrome

91 (6.7)

37 (10.4)

29 (8.9)

16 (4.8)

9 (2.5)

<0.001

Extent of coronary artery stenosis at baseline coronary angiography

    

No significant stenosis

234 (17.2)

44 (12.4)

67 (20.6)

58 (17.5)

65 (18.4)

0.09

1-vessel disease

368 (27.0)

134 (37.7)

74 (22.8)

85 (25.7)

75 (21.2)

<0.001

2-vessel disease

329 (26.3)

91 (25.6)

82 (25.2)

94 (28.4)

92 (26.1)

0.35

3-vesseldisease

403 (29.5)

86 (24.2)

102 (31.4)

94 (28.4)

121 (34.3)

0.04

Medication following baseline coronary angiography

    

Acetylsalisylic acid

1175 (86.1)

316 (89.0)

276 (84.9)

284 (85.8)

299 (84.7)

0.14

ADP receptor blocker

322 (23.6)

118 (33.2)

75 (23.1)

60 (18.1)

69 (19.5)

<0.01

Statins

1107 (81.2)

309 (87.0)

263 (80.9)

255 (77.0)

280 (79.3)

0.01

β-blockers

1022 (74.9)

268 (75.5)

235 (72.5)

248 (74.9)

271 (77.0)

0.43

ACE inhibitors

272 (19.9)

75 (21.1)

64 (19.7)

60 (18.1)

73 (20.7)

0.36

Loop diuretika

145 (10.6)

26 (7.3)

32 (9.8)

42 (12.7)

45 (12.7)

0.11

Fatty acids

      

Total fatty acids (mg/L)

3932 (3320, 4673)

3913 (3225, 4646)

3881 (3345, 4490)

3883 (3293, 4570)

4114 (3407, 4835)

0.02

Trans fatty acid (mg/L)

17.8 (13.3, 23.8)

11.5 (8.97, 14.0)

15.8 (13.3, 18.7)

19.6 (16.5, 23.1)

26.9 (22.3, 33.8)

<0.001

Trans 16:1n7 (mg/L)

2.64 (1.91, 3.68)

1.75 (1.36, 2.24)

2.46 (1.89, 3.09)

2.95 (2.40, 3.77)

3.81 (2.93, 4.94)

<0.001

Trans 18:1 (mg/L)

15.0 (11.2, 20.2)

9.66 (7.57, 11.8)

13.3 (11.2, 15.6)

16.4 (14.0, 19.7)

22.9 (18.8, 29.1)

<0.001

Lipid related parameters

     

ApoA1 (g/L)

1.29 (1.14, 1.46)

1.31 (1.17, 1.49)

1.31 (1.14, 1.48)

1.28 (1.13, 1.43)

1.26 (1.12, 1.45)

<0.01

ApoB (g/L)

0.91 (0.76, 1.07)

0.89 (0.76, 1.06)

0.91 (0.76, 1.07)

0.91 (0.74, 1.08)

0.92 (0.78, 1.07)

0.16

Cholesterol (mmol/L)

5.00 (4.30, 5.80)

5.00 (4.30, 5.70)

5.10 (4.40, 5.95)

5.00 (4.30, 5.90)

5.10 (4.30, 5.80)

0.33

HDL Cholesterol (mmol/L)

1.20 (1.00, 1.43)

1.20 (1.00, 1.40)

1.20 (1.00, 1.50)

1.20 (1.00, 1.40)

1.17 (0.94, 1.40)

1.00

Triglycerides (mmol/L)

1.52 (1.13, 2.15)

1.44 (1.08, 2.18)

1.48 (1.13, 1.92)

1.49 (1.08, 2.02)

1.67 (1.20, 2.40)

0.01

Lp(a) (mmol/L)

0.21 (0.10, 0.54)

0.25 (0.11, 0.59)

0.22 (0.10, 0.54)

0.19 (0.09, 0.48)

0.22 (0.10, 0.54)

0.11

Other parameters

     

Glucose (mmol/L)

5.70 (5.10, 6.70)

5.80 (5.10, 6.80)

5.60 (5.10, 6.50)

5.60 (5.20, 6.50)

5.70 (5.00, 6.80)

1.00

HbA1c (mmol/L)

5.84 (5.17, 6.54)

5.77 (5.19, 6.38)

5.77 (5.12, 6.44)

5.95 (5.22, 6.65)

5.87 (5.09, 6.73)

0.11

Arginine (μmol/L)

71.5 (50.9, 90.5)

77.8 (56.0, 96.5)

70.4 (51.2, 87.7)

65.3 (50.2, 88.2)

71.6 (49.1, 91.1)

<0.01

ADMA (μmol/L)

0.59 (00.50, 0.70)

0.54 (0.48, 0.65)

0.57 (0.49, 0.68)

0.61 (0.52, 0.74)

0.61 (0.52, 0.74)

<0.001

eGFR (mL/min)

91.0 (78.0, 99.0)

96.0 (85.0, 103)

90.0 (79.0, 99.0)

89.0 (77.0, 98.0)

87.0 (70.5, 97.5)

<0.001

CRP (mg/L)

1.92 (0.95, 3.98)

2.18 (1.00, 4.28)

1.82 (0.89, 3.91)

1.82 (0.97, 3.66)

1.97 (1.00, 3.77)

0.40

  1. Abbreviations: ApoA-1 apolipoprotein A-1, BCA baseline coronary angiography, BMI body mass index, CRP C-reactive protein, GFR glomerular filtration rate, HbA1c hemoglobin A1c, HDL high density lipoprotein, LDL low density lipoprotein, Lp(a) lipoprotein(a), PCI percutanous coronary intervention, wt% percentage by weight
  2. aMedian (range)
  3. bMedian linear regression for continuous and logistic regression for categorical variables
  4. cCount (percentage) for all such values
  5. dMedian (25th, 75th percentile) for all such values